Kafi Thomas
Internal Medicine · New York, NYNPI 1376064246
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,316 of the $3,911 with a category attached, or 84.8%. It is spread thinly across 31 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,994 and has fallen 69.0% since, to $617 in 2025.
Across 137 payments — averaging $28.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$696
- AstraZeneca$522
- Daiichi Sankyo Inc.$216
- Sanofi$214
- Regeneron Healthcare Solutions, Inc.$206
- Incyte Corporation$205
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,31685%
- Education$59515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 24 | $696 |
| AstraZeneca(2 entities) | 16 | $522 |
| Daiichi Sankyo Inc. | 10 | $216 |
| Sanofi | 7 | $214 |
| Regeneron Healthcare Solutions, Inc. | 6 | $206 |
| Incyte Corporation | 5 | $205 |
| Taiho Oncology, Inc. | 8 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $174 |
| E.r. Squibb & Sons, L.L.C. | 2 | $163 |
| Gilead | 3 | $149 |
| Bayer | 6 | $145 |
| Pfizer | 5 | $121 |
| Sumitomo Pharma America, Inc. | 4 | $115 |
| Lilly USA, LLC | 3 | $102 |
| Puma Biotechnology, Inc. | 5 | $96 |
| Merck | 3 | $88 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Kyowa Kirin, Inc. | 3 | $75 |
| Genentech USA, Inc. | 3 | $50 |
| Novartis | 2 | $41 |
| Eisai Inc. | 2 | $40 |
| Array Biopharma Inc | 2 | $35 |
| Karyopharm Therapeutics Inc. | 1 | $34 |
| Blueprint Medicines Corporation | 1 | $27 |
| Servier Pharmaceuticals LLC | 1 | $24 |
| Sobi, Inc | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Seagen Inc. | 1 | $21 |
| Deciphera Pharmaceuticals Inc. | 1 | $20 |
| Legend Biotech USA Inc. | 1 | $14 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,911 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 11 | $268 |
| Ondansetron Hcl | 18 | $230 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.